Aktuelle News
News Funktionen
Weitere Funktionen
29 April 2024
Biophytis
Biophytis is deploying its partnership strategy in obesity
24 April 2024
Biophytis
Biophytis Announces Transfer of ADSs to OTC Market
19 April 2024
Biophytis
Biophytis announces ratio change under its American Depositary Receipt (“ADR”) program
18 April 2024
Biophytis
Biophytis announces new Scientific Advisory Board for its phase 2 OBA clinical study in obesity
8 April 2024
Biophytis
Biophytis announces its 2023 financial results and provides an update on its business activities
Biophytis
Biophytis announces its 2023 financial results and provides an update on its business activities
Biophytis
Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone)
4 April 2024
Biophytis
RESULTS OF THE COMBINED GENERAL MEETING ON APRIL 2, 2024
22 März 2024
Biophytis
Biophytis presented its phase 3 protocol in the treatment of sarcopenia
17 November 2023
Biophytis
Biophytis announces receipt of Nasdaq Notice
30 Oktober 2023
Biophytis
Biophytis and Innovation Solutions Pharma sign a partnership agreement to accelerate market access for Sarconeos (BIO101) in Brazil
27 Oktober 2023
Biophytis
Biophytis receives notice of delisting from Nasdaq and announces it will request a hearing before the Nasdaq Hearings Panel
27 September 2023
Biophytis
Biophytis releases its half-yearly accounts as of 30 June 2023 and provides an update on its operations
25 September 2023
Biophytis
Biophytis and Skyepharma sign a Partnership Agreement for the Production of Sarconeos (BIO101)
19 September 2023
Biophytis
Biophytis provides an update on its early access programs for Sarconeos (BIO101) in the treatment of severe forms of COVID-19
14 September 2023
Biophytis
Biophytis Strengthens its Management Team with the Appointment of its Chief Business Officer
11 September 2023
Biophytis
Biophytis obtains FDA Authorization to initiate the SARA-31 phase 3 study in sarcopenia
4 September 2023
Biophytis
Biophytis to Participate at the H.C. Wainwright 25th Global Investment Conference in New York
16 August 2023
Biophytis
Biophytis announces next regulatory steps in Europe and the United States for its COVA project
8 August 2023
Biophytis
Biophytis receives a positive opinion for its SARA-31 phase 3 study in sarcopenia in Europe
20 Juli 2023
Biophytis
Biophytis: Biophytis has requested a pre-submission meeting with the FDA for an Emergency Use Authorization of Sarconeos (BIO101) for the treatment of COVID-19
19 Juli 2023
Biophytis
Biophytis Announces $3.8 Million Registered Direct Offering
18 Juli 2023
Biophytis
Biophytis and SEQENS sign a partnership to produce Sarconeos (BIO101) active compound
10 Juli 2023
Biophytis
Biophytis has filed with the FDA for authorization to initiate SARA-31 phase 3 study in sarcopenia
19 Juni 2023
Biophytis
Biophytis reports clinical results for Sarconeos (BIO101) in sarcopenia treatment at the 16th SCWD International Congress
16 Juni 2023
Biophytis
Biophytis: RESULTS OF THE ANNUAL GENERAL MEETING ON JUNE 16, 2023 ALL RESOLUTIONS PRESENTED BY THE COMPANY HAVE BEEN ADOPTED
5 Juni 2023
Biophytis
Biophytis to participate at the BIO International Convention in Boston from the 5th to the 8th of June
26 Mai 2023
Biophytis
Biophytis has filed with the French National Authority for Health (HAS) an application for Early Access Authorisation (EAA) for Sarconeos (BIO101) in the treatment of severe forms of COVID-1
25 Mai 2023
Biophytis
Biophytis Presented Positive Results of Phase 2-3 COVA Study At The American Thoracic Society International Conference
15 Mai 2023
Biophytis
Biophytis has filed with the EMA for authorization to initiate SARA-31 phase 3 study in sarcopenia